ReviewMediterranean journal of hematology and infectious diseases2018

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Masafumi Taniwaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.